Chris Venters received his B.S. in Biology from Duke University in 2011 where he Graduated with Distinction for his research thesis on structural studies of a Drosophila melanogaster myosin protein. He then received his Ph.D. in Biology from the University of Pennsylvania in 2019 where he conducted cell and molecular research on the function of several specific spliceosomal proteins and ribonucleoproteins both in human and other model organisms. During his doctoral research, he also developed many bioinformatics workflows to examine the impact of these RNA splicing and processing proteins in various diseases using large RNA and DNA sequencing datasets. Before joining Myers Bigel, Chris partnered with a Durham-based scientific entrepreneur to help launch a biotech startup in the RTP focused on phenotypic screening for small molecule drug discovery to target RNA processing diseases. As the Lead Biologist, Chris helped to design a business plan, raise seed money, recruit a research team, and build a target identification pipeline for the screening platform.